0:01Hello, this is Fred Kusumoto, reporting to you from Madrid from the
0:06European Society of Cardiology.
0:10This is the first of four daily wrap-ups.
0:14It's going to be part of the ACC coverage of the meeting.
0:19I'd like to highlight a couple of different trials that were presented
0:23at the hotline here today.
0:25The first is a trial called Podcast.
0:28Fascinating study.
0:29Taking patients who had an ICD and a low potassium of 4.3 and randomizing
0:34them either to usual care or trying to then follow them and monitor them to keep their potassium between 4.5 and 5.0.
0:44And after follow-up, those patients who had that intensive potassium monitoring,
0:49keeping them at a higher level potassium, in fact, had a significant reduction in their composite endpoint,
0:57which was mainly driven by the use of appropriate ICD therapies.
1:04So, for example, those patients who had that higher potassium target, in fact, had reduced appropriate ATP
1:14and reduced appropriate shocks.
1:18This is a fascinating study and it shows that something very, very simple
1:23can lead to very important changes.
1:26And one wonders whether or not this is something that could be generalizable more broadly.
1:33The second study is Digit Heart Failure.
1:36This is a study of 1200 patients with heart failure with reduced ejection fraction with different criteria
1:45based on their heart failure symptoms.
1:48But after about 40-month follow-up,
1:53those patients who were randomized to digit uh digitoxin were in fact associated
2:02or had reduced heart failure hospitalizations and overall mortality.
2:09Really with both, in fact, showing a benefit.
2:15Again, it's important for us to remember to not conflate in this case to the use of Dejaxin, remember that digitoxin and Dejaxin
2:30are excreted in different ways, whether by the liver or by the kidney respectively.
2:35So again, we'll have to wait for decision to see if in fact these sorts of results
2:40are transferable in fact to then those patients who are receiving Dejaxin therapy.
2:48But it is exciting.
2:49I mean, I think of Dejaxin, I remember how important it was when I first started training and went through a wall,
2:58and now it seems to be going through a renaissance where we use it.
3:03The last trial is Amolphy.
3:05Again, an interesting study where they took patients who were older and at higher risk for stroke
3:12 and randomized them either to usual care for identifying atrial fibrillation or a 14-day recorder.
3:20Not surprisingly, those patients who had the 14-day recorder mailed to them
3:26had a higher incidence of atrial fibrillation, but it wasn't much.
3:31It was 6.8% versus 5.4%.
3:35Really striking and important in fact that the main takeaway, at least for me, is that we're getting a little bit more cognizant
3:50of the importance of identifying atrial fibrillation,
3:55whether it's us as healthcare providers or our patients.
3:59And I think that this is going to be important
4:03 and may attenuate the impact of wearables and other types of methods for identifying atrial fibrillation early.
4:14I hope you enjoyed this first daily wrap-up.
4:19Join us tomorrow as I am joined by Eugenia Jonos and we're going to really focus on the prevention aspect for the hotline to.
4:30Take care now.
4:31Bye-bye.
